Answers are grounded in this paper and cite their sources.
SARS-CoV-2 has held the world hostage over the last 3 years, constantly mutating to elude therapeutic measures, with 765,903,278 documented cases and 6,927,378 deaths as of May 17 th , 2023. During this time, biotechnology hastened advancement of preventive measures, with healthcare professionals repurposing the use of existing medications to manage the onslaught of infections and deaths. In this retrospective review, we revisit the emergency use authorization of nascent vaccines, repurposing of non-antiviral medications and stand-by convalescent plasma and immunotherapies while welcoming the development of innovative gene editing tools.
No takes yet. Share an insight, caveat, or question.
Tym et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: